C07K 2317/569
Single domain
Official title: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
C07K2317/569 (Single domain) appears on 1,536 US grants and 3,679 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,536
- Published applications
- 3,679
- Assignees
- 1,234
- Inventors
- 6,321
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 2 |
| 2003 | 1 | 4 |
| 2004 | 1 | 4 |
| 2005 | 2 | 11 |
| 2006 | 1 | 21 |
| 2007 | 4 | 19 |
| 2008 | 2 | 26 |
| 2009 | 4 | 38 |
| 2010 | 11 | 62 |
| 2011 | 9 | 83 |
| 2012 | 17 | 65 |
| 2013 | 23 | 83 |
| 2014 | 40 | 75 |
| 2015 | 53 | 119 |
| 2016 | 57 | 125 |
| 2017 | 88 | 152 |
| 2018 | 104 | 194 |
| 2019 | 103 | 187 |
| 2020 | 111 | 223 |
| 2021 | 139 | 264 |
| 2022 | 132 | 292 |
| 2023 | 118 | 337 |
| 2024 | 178 | 470 |
| 2025 | 203 | 443 |
| 2026 | 135 | 380 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Aggrecan binding immunoglobulins6 Oct 2026US 12,753,224 B2Ablynx N. V.
- Compositions and methods for genetically-encoded high voltage-activated calcium channel blockers using engineered ubiquitin ligases6 Oct 2026US 12,753,228 B2The Trustees of Columbia University in the City of New York
- Fusion protein comprising anti-CD3 single domain antibody, exosomal protein CD63 and RNA binding protein, and uses thereof6 Oct 2026US 12,753,232 B1China Medical University Hospital
- Methods of cancer treatment with PD-L1 targeted interferon therapeutic agents6 Oct 2026US 12,753,233 B2Orionis Biosciences BV
- Targeting of human interferon antagonists22 Sep 2026US 12,741,998 B2Centre Hospitalier Regional Universitaire De Montpellier
- Lipid nanoparticles and methods of manufacture and use thereof8 Oct 2026US 2026/0306659 A1Ablynx N. V.
- Targeted engineered interferon and uses thereof8 Oct 2026US 2026/0308221 A1Orionis Biosciences BV
- Multi-domain molecules8 Oct 2026US 2026/0308260 A1Immunocore Limited
- Colony stimulating factor 1 receptor antibodies and methods of use thereof8 Oct 2026US 2026/0308263 A1Otsuka Pharmaceutical Co., Ltd.
- Il12rb2 binding molecules and methods of use8 Oct 2026US 2026/0308265 A1Synthekine, Inc.
Most cited
By later US patents
- Anti-VEGF antibodies335US 6,884,879 B1Genentech, Inc. · 2005
- Anti-PD1 antibodies and their use as therapeutics and diagnostics285US 8,735,553 B1BeiGene, Ltd. · 2014
- Anti-VEGF antibodies165US 7,060,269 B1Genentech, Inc. · 2006
- Stably tethered structures of defined compositions with multiple functions or binding specificities139US 7,521,056 B2IBC Pharmaceuticals, Inc. · 2009
- Nucleic acid-polypeptide compositions and uses thereof85US 10,550,188 B2Avidity Biosciences, Inc. · 2020